Abelacimab is under clinical development by Anthos Therapeutics and currently in Phase I for Venous (Vein) Thrombosis. According to GlobalData, Phase I drugs for Venous (Vein) Thrombosis have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Abelacimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Abelacimab overview

Abelacimab is under development for the prevention of venous thrombosis, cancer associated venous thromboembolism (VTE), pulmonary embolism, deep vein thrombosis, stroke and systemic embolism in patients with atrial fibrillation. The therapeutic candidate is an anti-FXI monoclonal antibody and is a new molecular entity. It acts by targeting coagulation factor XI. It is administered through subcutaneous, intravenous and oral routes. The drug candidate was also under development for arterial thrombosis and inflammation.

Anthos Therapeutics overview

Anthos Therapeutics is a healthcare company engaged in the research and development of genetically and pharmacologically validated therapies for cardiovascular and metabolic (CVM) diseases. The company is headquartered in Cambridge, Massachusetts, the US.

For a complete picture of Abelacimab’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 May 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.